{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:34:48Z","timestamp":1760783688535},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.neuropharm.2013.05.038","type":"journal-article","created":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T12:27:45Z","timestamp":1371040065000},"page":"232-240","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test"],"prefix":"10.1016","volume":"73","author":[{"given":"Snjezana","family":"Lelas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya L.","family":"Wallace-Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Taber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy E.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick L.","family":"Pieschl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus F.","family":"Molski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly S.","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne J.","family":"Bronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Macor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.05.038_bib1","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","article-title":"Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone","volume":"19","author":"Campos","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib2","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade","year":"2009","journal-title":"Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib3","first-page":"253","article-title":"Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test","volume":"172","author":"Chenu","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4088\/JCP.v62n0309","article-title":"Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction","volume":"62","author":"Clayton","year":"2001","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14728214.2012.660146","article-title":"Emerging drugs for major depressive disorder","volume":"17","author":"Connolly","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1755-5949.2008.00067.x","article-title":"Vilazodone: a 5-HT1A receptor agonist\/serotonin transporter inhibitor for the treatment of affective disorders","volume":"15","author":"Dawson","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib7","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1073\/pnas.0400794101","article-title":"Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats","volume":"101","author":"Ebner","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib8","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1523\/JNEUROSCI.21-20-08188.2001","article-title":"5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization","volume":"21","author":"Froger","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1176\/ajp.2006.163.4.637","article-title":"Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression","volume":"163","author":"Geracioti","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bmcl.2012.11.094","article-title":"Design, optimization, and in\u00a0vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression","volume":"23","author":"Gillman","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.euroneuro.2006.07.004","article-title":"Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function","volume":"17","author":"Gobbi","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.bjp.0706697","article-title":"[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain","volume":"148","author":"Griffante","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1471-4159.2003.02304.x","article-title":"Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in\u00a0vivo microdialysis study in mice","volume":"89","author":"Guiard","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0269881112472558","article-title":"Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans","volume":"27","author":"Harmer","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","article-title":"Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone","volume":"510","author":"Hughes","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib16","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Institute of Laboratory Animal Resources","year":"1996"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder","volume":"59","author":"Keller","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.npp.1300260","article-title":"Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression","volume":"29","author":"Kramer","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib19","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bcp.2009.01.020","article-title":"Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3","volume":"77","author":"Leffler","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib20","first-page":"28,156","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder","author":"Marcus","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib21","first-page":"86","article-title":"Imaging the serotonin transporter during major depressive disorder and antidepressant treatment","volume":"32","author":"Meyer","year":"2007","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.euroneuro.2010.04.003","article-title":"S41744, a dual neurokinin (NK)1 receptor antagonist and\u00a0serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine","volume":"20","author":"Millan","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib23","first-page":"1305","article-title":"Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites","volume":"283","author":"Owens","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib24","first-page":"33","article-title":"Excitatory amino acid signalling, major depression and the actions of antidepressants","volume":"8","author":"Paul","year":"2001","journal-title":"Pharm. News"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/JCP.0b013e31823608ca","article-title":"Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1receptor antagonist casopitant in patients with major depressive disorder","volume":"31","author":"Ratti","year":"2011","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib26","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib27","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/S0960-894X(02)00563-2","article-title":"Dual NK1 antagonists\u2014serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives","volume":"12","author":"Ryckmans","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2013.05.038_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0893-133X(02)00313-5","article-title":"The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists","volume":"27","author":"Varty","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.038_bib29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.npp.1301586","article-title":"Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists","volume":"33","author":"Wallace-Boone","year":"2008","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T07:27:07Z","timestamp":1563175627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":29,"alternative-id":["S0028390813002529"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.038","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}